Table 3 Comorbidity and Treatment in patients with autoimmune hepatitis in 2018 and 2015.
From: Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan
No. of patients | 2015 versus 2018 | ||
|---|---|---|---|
2018 | 2015 | P | |
Comorbidity | |||
Autoimmune disorder | 24.7% (194/787) | 24.9% (347/1,395) | 0.948 |
Chronic thyroiditis | 8.3% (65) | 8.0% (111) | |
Sjögren’s syndrome | 6.6% (52) | 6.6% (92) | |
Rheumatoid arthritis | 2.7% (21) | 3.7% (51) | |
Primary biliary cholangitis | 2.4% (19) | 2.8% (39) | |
Systemic sclerosis | 1.8% (14) | 0.8% (11) | |
Graves’ disease | 1.8% (14) | 1.1% (16) | |
Systemic lupus erythematosus | 1.5% (12) | 2.4% (34) | |
Idiopathic thrombocytopenic purpura | 0.6% (5) | 0.7% (10) | |
Raynaud’s phenomenon | 0.5% (4) | 0.9% (12) | |
Dermatomyositis/polymyositis | 0.5% (4) | 0.4% (6) | |
Others | 2.3% (18) | 1.9% (26) | |
Malignancy | 10.3% (81/784) | 6.4% (88/1,383) | 0.001 |
Gastric cancer | 1.8% (14) | 0.8% (11) | |
Colon cancer | 1.7% (13) | 0.7% (9) | |
Breast cancer | 1.7% (13) | 1.0% (14) | |
Uterine or ovarian cancer | 1.0% (8) | 0.4% (6) | |
Lung cancer | 0.9% (7) | 0.5% (7) | |
Hepatocellular carcinoma | 0.6% (5) | 0.8% (11) | |
Others | 2.9% (23) | 2.2% (31) | |
Treatment | |||
Prednisolone | 85.5% (665/778) | 80.9% (1,129/1,396) | 0.008 |
Prednisolone alone | 31.8% (204/642) | 30.0% (331/1,103) | 0.473 |
Initial dose of prednisolone (mg/day) | 40 (30–40) | 30 (30–40) | < 0.001 |
Maintenance dose of prednisolone (mg/day) | 5 (5–7.5) | 5(5–7.5) | 0.281 |
Steroid pulse therapy, n (%) | 19.1% (122/640) | 13.3% (138/1,036) | 0.002 |
Prednisolone + ursodeoxycholic acid | 63.0% (409/649) | 64.7% (714/1,103) | 0.503 |
Efficacy of prednisolone | 97.8% (575/588) | 97.6% (1,008/1,033) | 0.923 |
Relapse during prednisolone therapy | 23.2% (141/609) | 24.7% (247/1,000) | 0.520 |
Azathioprine | 12.3% (80/648) | 9.4% (128/1,362) | 0.051 |
Ursodeoxycholic acid alone | 10.9% (81/744) | 15.6% (213/1,362) | 0.003 |
Without treatment | 2.4% (18/744) | 2.0% (27/1,363) | 0.612 |
Biochemical remission after 6 months of therapy | 58.4% (330/565) | - | - |
